Goldman Sachs: Neutral rating on CHOW TAI FOOK (01929) with a target price of 10.5 Hong Kong dollars.
Chow Tai Fook management still has confidence in achieving the goal of a 25% return on equity (ROE) by the 2025 fiscal year.
Goldman Sachs released a research report stating that it gives CHOW TAI FOOK (01929) a "neutral" rating, based on a 3.5 times 2025 fiscal year price-to-book ratio, with a target price of 10.5 Hong Kong dollars.
At the Goldman Sachs China Investment Conference on September 11, 2024, CHOW TAI FOOK mentioned that the total retail sales value (RSV) pressure in the Mainland and Hong Kong and Macao markets in July and August was similar to that of the June quarter. The company is more cautious about store expansion, expecting a closure rate of 5%-7% this year, so it will be more cautious in opening new stores, prioritizing store productivity.
Furthermore, the management still has confidence in achieving a target return on equity (ROE) of 25% for the 2025 fiscal year. The dividend payout ratio is expected to remain stable at 70%-80%, with limited cash flow pressure to de-stock. The company hopes to improve its net debt ratio from 78% at the end of the 2024 fiscal year to 50-60% (including gold loans).
Related Articles

New Stock News | Tiantian Biomedical has once again submitted documents to the Hong Kong Stock Exchange and has launched eight clinical trials in China related to LP-003.

Zhongtai: Continue grasping the structural pharmaceutical market and continue to focus on medical AI+ solutions.

New stock news | Ronglian Regeneration Technology's Hong Kong IPO prospectus expires.
New Stock News | Tiantian Biomedical has once again submitted documents to the Hong Kong Stock Exchange and has launched eight clinical trials in China related to LP-003.

Zhongtai: Continue grasping the structural pharmaceutical market and continue to focus on medical AI+ solutions.

New stock news | Ronglian Regeneration Technology's Hong Kong IPO prospectus expires.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


